The two companies have obtained final OTC approval to sell a generic version of Sanofi-Aventis's Allegra allergy treatment.
Perrigo Company (Nasdaq:PRGO; TASE:PRGO) and Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) have obtained final OTC approval to sell a generic version of Sanofi-Aventis SA's (NYSE: SNY; Euronext: SAN) Allegra allergy treatment. Teva and Sanofi-Aventis have settled their Paragraph IV/Hatch-Waxman litigation relating to the Allegra brand family of products.
Teva's is Perrigo's partner to market generic fexofenadine HCl. Brand Allegra sales totaled $600 million in the US in 2009.
Teva has marketed generic Allegra since 2005, and Perrigo bought the marketing rights in June 2009.
Published by Globes [online], Israel business news - www.globes-online.com - on April 14, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011